Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia
| Autor: | Jianyong Li, Yao He, Lang Cheng, Jian-Fu Zhang, Ming Hong, Ruinan Lu, Guangsheng He, Xiaoqing Liu, Run Zhang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Acquired Pure Red Cell Aplasia Bilirubin Eltrombopag Pure red cell aplasia Red-Cell Aplasia Pure Benzoates Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Refractory Bone Marrow hemic and lymphatic diseases Internal medicine medicine Humans Erythropoiesis Reticulocytopenia Hematology business.industry Middle Aged medicine.disease stomatognathic diseases Hydrazines Treatment Outcome chemistry 030220 oncology & carcinogenesis Pyrazoles business Receptors Thrombopoietin 030215 immunology |
| Zdroj: | International Journal of Hematology. 114:124-128 |
| ISSN: | 1865-3774 0925-5710 |
| DOI: | 10.1007/s12185-021-03100-2 |
| Popis: | Acquired pure red cell aplasia is a rare condition characterized by normocytic normochromic anemia with severe reticulocytopenia. In refractory acquired pure red cell aplasia, the low response rate of immunosuppressive therapy also constitutes a challenge. We herein report the case of a 58-year-old male with refractory acquired pure red cell aplasia that was successfully treated by eltrombopag at a dose of 75 mg/day. After application of eltrombopag, the patient achieved complete remission and tolerated the treatment very well, with only mild bilirubin elevation. These preliminary findings showed that eltrombopag may be effective and well tolerated in adult patients with refractory acquired pure red cell aplasia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink